PubMed Health⌕ Search

Biomedical subjects

Tim Meyer

Publications and source records attributed to Tim Meyer.

20 records · Page 2Linked to original sources

[Exercise training in heart failure].

BACKGROUND: In patients with chronic heart failure, exercise limitation cannot be exclusively attributed to cardiac dysfunction. During progression of the disease, peripheral factors have a growing impact on functional capacity. Chronic underperfusion of skeletal muscles, inactivity and a harmful effect of neuroendocrine stimulation lead to a myopathy syndrome characterized by atrophy, a shift in muscle fiber type and a loss of capillaries and mitochondria, which cause reduced muscle strength and aerobic capacity. Unlike left ventricular systolic function, which is a poor predictor of exercise tolerance in patients with chronic heart failure, parameters characterizing the myopathy syndrome correlate well with functional capacity. In the last 20 years, numerous studies have demonstrated that chronic heart failure patients in NYHA classes II and III benefit from physical training without deterioration of their cardiac function. EFFECTS OF EXERCISE TRAINING: Physical activity primarily improves muscle function and increases maximal as well as submaximal exercise capacity. Advantageous effects have also been observed with regard to neuroendocrine stimulation. The effect on central hemodynamics is much smaller and indirectly mediated by a trend towards decreased peripheral resistance. Left ventricular diameters, ejection fraction and filling pressures do not show significant changes. The gain in exercise capacity is usually accompanied by an improvement in symptom status and quality of life. Recent studies indicate that prognosis may also be improved by exercise training. CONVERSION INTO CLINICAL PRACTICE: Although continuous exercise training (mainly by use of cycle ergometry) has been investigated most thoroughly, there is an increasing number of studies reporting beneficial effects of interval and resistance training. Before starting a standardized training program, functional limitation and training intensity should be determined by an appropriate stress test. During the first training sessions, patients should always be supervised by a physician. In order to increase efficiency and feasibility of the exercise therapy, home-based training should be engaged as soon as a stable condition during repeated training sessions has been proven.

Chronic Disease↗

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

BACKGROUND: Chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, or whether embolization (TAE) alone gives the same survival advantage, is not known. PURPOSE: To evaluate whether specific patient characteristics and/or radiological transarterial techniques result in better outcomes. METHOD: A PubMed search was carried out for cohort and randomized trials (n = 175) testing transarterial therapies; meta-analysis was performed where appropriate. RESULTS: Anticancer drugs were used as sole agent in 75% of cases (double 15% and triple 6%): doxorubicin (36%), cisplatin (31%), epirubicin (12%), mitoxantrone (8%), mitomycin (8%), and SMANCS (5%). Embolizing agents used were: gelatin sponge particles (71%), polyvinyl alcohol (PVA) particles (8%), degradable starch microspheres (DSM) (4%), and embospheres (4%). Sessions per patient were 2.5 +/- 1.5 (interval: 2 months). Objective response was 40 +/- 20%; survival rates at 1, 2, 3, and 5 years were: 62 +/- 20%, 42 +/- 17%, 30 +/- 15%, and 19 +/- 16%, respectively, and survival time was 18 +/- 9.5 months. The post-TACE complications were: acute liver failure, 7.5% (range 0-49%); acute renal failure, 1.8% (0-13%); encephalopathy, 1.8% (0-16%); ascites, 8.3% (0-52%); upper gastrointestinal bleeding; 3% (0-22%); and hepatic or splenic abscess, 1.3% (0-2.5%). Treatment-related mortality was 2.4% (0-9.5%), mainly due to acute liver failure. Our meta-analysis of nine randomized controlled trials (RCTs) confirmed that TACE improves survival; but a meta-analysis of TACE versus TAE alone (3 RCTs, 412 patients) demonstrated no survival difference. CONCLUSIONS: No chemotherapeutic agent appears better than any other. There is no evidence for benefit with lipiodol. Gelatin sponge is the most used embolic agent, but PVA particles may be better. TAE appears as effective as TACE. New strategies to reduce the risk of post-TACE complications are required.

Carcinoma, Hepatocellular↗